Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)

Citation
Ik. Wiklund et al., Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD), EURO J SURG, 164, 1998, pp. 41-49
Citations number
26
Categorie Soggetti
Surgery
Journal title
EUROPEAN JOURNAL OF SURGERY
ISSN journal
11024151 → ACNP
Volume
164
Year of publication
1998
Supplement
583
Pages
41 - 49
Database
ISI
SICI code
1102-4151(199812)164:<41:QOLIRA>2.0.ZU;2-M
Abstract
Objective. To develop a disease-specific QOL instrument (QOLRAD) addressing patient concerns in gastroesophageal reflux disease (GERD) and dyspepsia. Patients. 759 male (45%) and female (55%) patients with a mean age of 48.4 years (sd 15.2) were used in the psychometric evaluation. Main outcome measures. A pilot version of QOLRAD, the Gastrointestinal Symp toms Rating Scale (GSRS) and the SF-36 were completed prior to endoscopy. I tems with a high ceiling effect, items measuring a different construct, i.e . with a low squared multiple correlation (R < 0.5) with the other items, i tems that showed redundancy by a high correlation (>0.80) with another item were removed. A confirmatory factor analysis was also performed. Results. The final questionnaire included 25 items depicting problems with emotions, vitality, sleep, eating/drinking, and physical/social functioning . The internal consistency reliability was high (alpha value overall 0.97, dimensions 0.89-94). Construct validity, i.e. the associations between simi lar constructs in the QOLRAD, the SF-36 and the GSRS scores was confirmed. Pain and symptom severity were markers of impaired QOL. The impact on healt h-related QOL was similar across the functional gastrointestinal disorders with the exception of patients with a normal endoscopy, who did slightly wo rse. Conclusion. The QOLRAD is a shea and user-friendly instrument with excellen t psychometric properties. Its responsiveness to change in (AVMCl)clinical trials is currently being explored.